- Home
- INVE vs CNTX Comparison
INVE vs CNTX Comparison
Compare INVE & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- CNTX
- Stock Information
- Founded
- INVE 1990
- CNTX 2015
- Country
- INVE United States
- CNTX United States
- Employees
- INVE N/A
- CNTX N/A
- Industry
- INVE Computer peripheral equipment
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- INVE Technology
- CNTX Health Care
- Exchange
- INVE Nasdaq
- CNTX Nasdaq
- Market Cap
- INVE 82.2M
- CNTX 78.0M
- IPO Year
- INVE 1997
- CNTX 2021
- Fundamental
- Price
- INVE $3.09
- CNTX $0.58
- Analyst Decision
- INVE Strong Buy
- CNTX Strong Buy
- Analyst Count
- INVE 3
- CNTX 4
- Target Price
- INVE $6.50
- CNTX $6.00
- AVG Volume (30 Days)
- INVE 35.0K
- CNTX 390.0K
- Earning Date
- INVE 08-07-2025
- CNTX 08-06-2025
- Dividend Yield
- INVE N/A
- CNTX N/A
- EPS Growth
- INVE N/A
- CNTX N/A
- EPS
- INVE 3.12
- CNTX N/A
- Revenue
- INVE $25,239,000.00
- CNTX N/A
- Revenue This Year
- INVE N/A
- CNTX N/A
- Revenue Next Year
- INVE $9.00
- CNTX N/A
- P/E Ratio
- INVE $0.99
- CNTX N/A
- Revenue Growth
- INVE N/A
- CNTX N/A
- 52 Week Low
- INVE $2.86
- CNTX $0.49
- 52 Week High
- INVE $4.44
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- INVE 40.43
- CNTX 44.00
- Support Level
- INVE $3.12
- CNTX $0.56
- Resistance Level
- INVE $3.23
- CNTX $0.63
- Average True Range (ATR)
- INVE 0.11
- CNTX 0.08
- MACD
- INVE -0.02
- CNTX 0.00
- Stochastic Oscillator
- INVE 0.00
- CNTX 27.68
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has two reportable segments namely the Premises segment which includes solutions to address the premises security market for government and enterprise, including access control, video surveillance, analytics, customer experience, and other applications. Its Identity segment includes products and solutions enabling secure access to information serving the logical access and cyber security market and protecting assets and objects in the IoT with RFID. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific. The company derives the majority of revenue from the Identity segment.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.